[1]王颖,蔡莉,李彦生,等.11C-PIB PET在不同时期阿尔茨海默病中的研究进展[J].国际放射医学核医学杂志,2013,37(6):378-380,384.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
　WANG Ying,CAI Li,LI Yan-sheng,et al.Application of 11C-PIB PET in different period of the Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):378-380,384.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
点击复制

11C-PIB PET在不同时期阿尔茨海默病中的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第6期
页码:
378-380,384
栏目:
综述
出版日期:
2013-11-25

文章信息/Info

Title:
Application of 11C-PIB PET in different period of the Alzheimer disease
作者:
王颖;  蔡莉;  李彦生;  高硕
天津医科大学总医院PET/CT中心, 天津 300052
Author(s):
WANG Ying;  CAI Li;  LI Yan-sheng;  GAO Shuo
PET/CT Center, General Hospital of Tianjin Medical University, Tianjin 300052, China
关键词:
阿尔茨海默病; 淀粉样β蛋白; 正电子发射断层显像术
Keywords:
Alzheimer’s disease; Amyloid beta-protein; Positron-emission tomography
DOI:
10.3760/cma.j.issn.1673-4114.2013.06.013
摘要:
阿尔茨海默病(AD)作为神经变性病,起病隐袭,早期诊断困难.β淀粉样蛋白(Aβ)沉积形成的老年斑是其特征性病理改变,并且发生在疾病的早期阶段.N-[11C]甲基-2-4’-甲基氨基苯基-6-羟基苯并噻唑(11C-PIB)作为Aβ特异性的分子探针,能够无创、实时、定量地监测脑内纤维状Aβ的变化.因此,明确PIB在不同时期AD中的分布特点,对AD的早期诊断、抗Aβ治疗的人群筛选以及疗效监测方面都具有重要意义.该文就近年来11C-PIB PET在不同时期AD中的应用作一综述.
Abstract:
Alzheimer disease (AD) is a neurodegenerative disease.It is difficult to make an early diagnosis because it is insidious onset.One of the neuropathological hallmarks of AD is the formation of senile plaques,which is composed of fibril amyloid β-protein (Aβ).And amyloid deposition is an early event on the path to dementia.N-[11C] methyl-2-4’-methylaminophenyl-6-hydroxybenzothiazole (11C-PIB) is a specific molecular probe of Aβ,which could monitor the change of fibril Aβ non-invasively,dynamically and quantitatively.In order to aid early diagnosis,screen the population for antiamyloid therapies and monitor the therapeutic effects,it is urgent to elucidate the PIB characteristics of distribution at different stage of AD.Therefore,the application of 11C-PIB PET in AD in the latest years will be summarized.

参考文献/References:

[1] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain, 2008, 131(Pt 6):1630-1645.
[2] Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci, 2007, 27(39):10365-10371.
[3] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol, 2004,55(3):306-319.
[4] Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s、disease. Alzheimers Dement, 2011, 7(3):257-262.
[5] Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer’s disease with Pittsburgh Compound B. J Neurosci Methods, 2008, 172(2):277-282.
[6] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain, 2008, 131(Pt6):1630-1645.
[7] Rabinovici GD, Jagust WJ. Amylòid imaging in aging and dementia:testing the amyloid hypothesis in vivo. Behav Neurol, 2009, 21(1):117-128.
[8] Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloi-dosis and risk prediction for Alzheimer dementia. Neurobiol Aging, 2011,32 Suppl 1:S20-36.
[9] Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci, 2007, 27(23):6174-6184.
[10] Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med, 2004,256(3):183-194.
[11] 程怀东,汪凯.遗忘型轻度认知损害的早期诊断途径:从分子、影像到行为神经病学.中国现代神经疾病杂志,2010, 10(2):155-159.
[12] Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals:evidence for preclinical Alzheimer’s disease. Brain, 2007, 130(Ptll):2837-2844.
[13] Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-pro-gression from mild cognitive impairment to Alzheimer’s disease. Brain, 2010, 133(11):3336-3348.
[14] Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med, 2009, 360(22):2302-2309.
[15] Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain, 2008, 131(Pt3):665-680.
[16] Jacobs B, Schall M, Prather M, et al. Regional dendritic and spine variation in human cerebral cortex:a quantitative golgi study. Cereb Cortex, 2001, 11(6):558-571.
[17] Attems J, Thai DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer’s disease. Biochem Soc Trans, 2012,40(4):711-715.
[18] Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134(Pt4):1077-1088.
[19] Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol, 2008, 65(11):1509-1517.
[20] Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol, 2010, 67(1):122-131.
[21] Price JL, Davis PB, Morris JC, et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging, 1991,12(4):295-312.
[22] Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer’s disease. Biochim Biophys Acta, 2012, 1822(3):370-379.
[23] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 2011,7(3):280-292.
[24] Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry, 2010, 67(6):584-587.
[25] Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab:a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 2010, 9(4):363-372.
[26] Alexander D, Robert P. Imaging amyloid in the human brain:a promising tool for improved early diagnosis and treatment monitoring in Alzheimer’s Disease. Open Nucl Med J, 2010, 2:53-57.

相似文献/References:

[1]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
　Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[2]段小艺,李淼,王黎,等.阿尔茨海默病PET正电子药物应用与研究进展[J].国际放射医学核医学杂志,2014,38(5):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
　Duan Xiao-yi,Li Miao,Wang Li,et al.Application and research progress of PET positron tracers associated with Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
[3]王新艳,管一晖.阿尔茨海默病的影像学诊断进展[J].国际放射医学核医学杂志,2013,37(1):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
　WANG Xin-yan,GUAN Yi-hui.The advancement in Alzheimer disease of imaging diagnosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
[4]孔艳艳,管一晖,吴平.PET分子探针在阿尔茨海默病早期诊断中的研究进展[J].国际放射医学核医学杂志,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
　KONG Yan-yan,GUAN Yi-hui,WU Ping.Novel PET molecular probes for early diagnosis of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
[5]张冰,徐俊,徐运,等.fMRI在阿尔茨海默病、额颞叶痴呆及路易体痴呆中的研究进展[J].国际放射医学核医学杂志,2010,34(5):303.[doi:10.3760/cma.j.issn.1673-4114.2010.05.015]
　ZHANG Bing,XU Jun,XU Yun,et al.The study of fMRI in Alzheimer’s disease, frontotemporal dementia and Lewy bodies dementia[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):303.[doi:10.3760/cma.j.issn.1673-4114.2010.05.015]
[6]陈贵兵,吴华,彭添兴.正电子显像剂11C-匹兹堡化合物B的化学合成及其临床应用[J].国际放射医学核医学杂志,2008,32(3):158.
　CHEN Gui-bing,WU Hua,PENG Tian-xing.Chemical synthesis and clinical application of a new positron imaging agent 11C-Pittsburgh compound-B[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):158.
[7]袁瑛,顾兆祥.放射性核素显像在轻度认知功能障碍中的应用价值[J].国际放射医学核医学杂志,2008,32(4):209.
　YUAN Ying,GU Zhao-xiang.Applications of radionuclide imaging in mild cognitive impairment[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):209.
[8]郭喆,张锦明.阿尔茨海默病的放射性分子显像探针研究进展[J].国际放射医学核医学杂志,2006,30(4):199.
　GUO Zhe,ZHANG Jin-ming.Study on radioactive labeling of molecular probes for Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):199.
[9]李祖贵.轻度认知障碍的功能性神经影像学研究进展[J].国际放射医学核医学杂志,2006,30(2):76.
　LI Zu-gui.The progress of functional neuroimaging in the study of mild cognitive impairment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):76.
[10]王瑞民.阿尔茨海默病等痴呆疾病的脑功能影像学研究[J].国际放射医学核医学杂志,2001,25(5):209.
　WANG Rui-min.Functional neuroimaging of Alzheimer’s disease and other dementias[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):209.
[11]蔡汉成,尹端沚,张岚,等.早期诊断阿尔茨海默病的PET分子探针[J].国际放射医学核医学杂志,2006,30(4):202.
　CAI Han-cheng,YIN Duan-zhi,ZHANG Lan,et al.PET molecular probes for early detection of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):202.

备注/Memo

备注/Memo:
收稿日期:2012-11-20。
通讯作者:高硕,Email:dr_shuogao@hotmail.com
更新日期/Last Update: 1900-01-01